Response Genetics (RGDX) Six New Provider Networks Contracts,

Response Genetics, Inc. (RGDX)

RGDX reported that it has signed agreements with six additional health plans across 10 states bringing the Company's total national contracted membership to more than 174 million lives.

With these agreements, RGDX is now in-network with a total of thirteen Blue Cross Blue Shield health plans, which brings the total number of "Blues" subscribers with direct access to RGDX to approximately 23 million. Among RGDX 's other Blue Cross Blue Shield contracts are Blue Cross and Blue Shield of Illinois, Blue Shield of California and CareFirst BlueCross BlueShield (Maryland, Washington, DC and Northern Virginia).

In addition to its recently launched proprietary ResponseDX: Tissue of Origin(TM) diagnostic test, RGDX 's molecular testing primarily focuses on therapy-selection for patients with lung, colon, gastric, melanoma, and thyroid cancers.

RGDX 's menu of genomic assays provides treating physicians actionable information on a patient's tumor by predicting which course of therapy will work best for that patient. In this way, RGDX 's participation with these Blues plans should improve plan members' access to individually-tailored medicine.

RGDX is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer.

More about Response Genetics, Inc. (RGDX) at www.responsegenetics.com .

**

Crown Equity Holdings Inc. (CRWE)

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

CRWE is currently developing its CRWE Network ( CRWE-PR.com ), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 323th community website in the U.S., associated with 1535 ZIP Codes , and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada

CRWE ‘s community targeted publications of websites will offer businesses’ owners the power of developing and publishing their own advertisement through the use of the CRWE Network’s platform to entice potential nearby consumers within its community with offers and deals. Advertisement on a national level is presently operational with local advertisement/coupon being available soon.

CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

Syneron Medical Ltd. (ELOS)

Stretch marks are one of the most common skin disorders, impacting 95% of women during puberty or pregnancy, and can also occur in men and children. Historically difficult to treat, striae occur when the skin is stretched from rapid growth or weight gain, and causes damage to the connective tissue in the dermis.

Acne is a common condition experienced by up to 85% of adolescents and young adults and 5% of older adults. In some patients, the healing process results in permanent, disfiguring scars. Treatments ranged from chemical peels to ablative procedures with long recovery times and risky side effects.

ELOS reported that its proprietary Sublative(TM) technology has received CE Mark indication for the effective treatment of striae (stretch marks) and acne scars.

ELOS ' Sublative has been shown to be an effective and safe way to reduce the appearance of stretch marks, acne scars and other skin irregularities in all skin types with minimal side effects, discomfort or downtime.

The unique patented technology uses fractionated bi-polar radiofrequency directed to the skin in the form of a matrix. Due to its unique design, energy is deposited in the skin to initiate a healing response with minimal epidermal disruption. Patients benefit from a comfortable treatment with significant outcomes avoiding the potential complications of more aggressive treatments.

After treatment with ELOS ' Sublative, the appearance of stretch marks and acne scars are greatly reduced.

ELOS is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.

More about Syneron Medical Ltd. (ELOS) at www.syneron.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer